Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Paul Verdin
OpenAlex ID:
A5081991955
Top companies and drugs by sales in 2023
2024
·
Paul Verdin
·
Nature Reviews Drug Discovery
·
42
Top companies and drugs by sales in 2024
2025
·
Paul Verdin
·
Nature Reviews Drug Discovery
·
21
Burgeoning oncology pipeline raises questions about sustainability
2018
·
Jon Moser
, Paul Verdin
·
Nature Reviews Drug Discovery
·
17
Top product forecasts for 2025
2024
·
Paul Verdin
·
Nature Reviews Drug Discovery
·
13
FDA new drug approvals in Q2 2024
2024
·
Paul Verdin
·
Nature Reviews Drug Discovery
·
8
Top product forecasts for 2024
2023
·
Paul Verdin
·
Nature Reviews Drug Discovery
·
8
FDA new drug approvals in Q1 2024
2024
·
Paul Verdin
·
Nature Reviews Drug Discovery
·
7
Top companies and drugs by sales in 2025
2026
·
Paul Verdin
·
Nature Reviews Drug Discovery
·
4
FDA new drug approvals in Q2 2025
2025
·
Paul Verdin
·
Nature Reviews Drug Discovery
·
4
Top product forecasts for 2026
2025
·
Paul Verdin
·
Nature Reviews Drug Discovery
·
3
FDA new drug approvals in Q3 2024
2024
·
Paul Verdin
·
Nature Reviews Drug Discovery
·
3
FDA new drug approvals in Q1 2026
2026
·
Paul Verdin
·
Nature Reviews Drug Discovery
·
1
FDA new drug approvals in Q3 2025
2025
·
Paul Verdin
·
Nature Reviews Drug Discovery
·
1
FDA new drug approvals in Q1 2025
2025
·
Paul Verdin
·
Nature Reviews Drug Discovery
·
1
FDA new drug approvals in Q3 2023
2023
·
Paul Verdin
·
Nature Reviews Drug Discovery
·
1
Next-generation therapeutics sustain momentum
2020
·
Paul Verdin
·
Biopharma Dealmakers
·
1
PDF
Next-generation therapeutics: cell and gene therapy gathers pace
2019
·
Paul Verdin
, Lisa Urquhart
·
Biopharma Dealmakers
·
1
FDA new drug approvals in Q3 2026
2026
·
Paul Verdin
·
Nature Reviews Drug Discovery
FDA new drug approvals in Q2 2026
2026
·
Paul Verdin
·
Nature Reviews Drug Discovery
Show more works
View as search
Works count:
19
Citation count:
136
H-index:
7
I10-index:
4
Year
Topic
Type
